Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Braithwaite I"" wg kryterium: Autor


Tytuł :
Randomised controlled trial of paracetamol or ibuprofen, as required for fever and pain in the first year of life, for prevention of asthma at age 6 years: paracetamol or ibuprofen in the primary prevention of asthma in Tamariki (PIPPA Tamariki) protocol.
Autorzy :
Tan E; Department of Surgery, University of Auckland, Auckland, New Zealand.; Emergency Department, Middlemore Hospital, Auckland, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.
McKinlay C; Liggins Institute, University of Auckland, Auckland, New Zealand.; Kids First Neonatal Care, Middlemore Hospital, Auckland, New Zealand.
Riley J; Medical Research Institute of New Zealand, Wellington, New Zealand.
Hoare K; School of Nursing, Massey University, Auckland, New Zealand.
Okesene-Gafa K; Department of Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand.; Department of Obstetrics and Gynaecology, Middlemore Hospital, Auckland, New Zealand.
Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand.
Sheridan N; School of Nursing, Massey University, Auckland, New Zealand.
Grant C; Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand.; General Paediatrics, Starship Children's Health, Auckland, Auckland, New Zealand.
Johnson D; Department of Pediatrics, Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.
Weatherall M; Rehabilitation, Teaching and Research Unit, University of Otago, Wellington, New Zealand.
Asher I; Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.
Dalziel SR; Cure Kids Chair of Child Health Research; Departments of Surgery and Paediatrics: Child and Youth Health, University of Auckland, Auckland, New Zealand .; Children's Emergency Department, Starship Children's Health, Auckland, New Zealand.
Pokaż więcej
Źródło :
BMJ open [BMJ Open] 2020 Dec 10; Vol. 10 (12), pp. e038296. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Acetaminophen*/therapeutic use
Asthma*/drug therapy
Asthma*/prevention & control
Child ; Humans ; Ibuprofen/therapeutic use ; Infant ; Multicenter Studies as Topic ; New Zealand ; Pain ; Primary Prevention ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.
Autorzy :
Pavord ID; Oxford Respiratory National Institute for Health Research Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: .
Holliday M; Medical Research Institute of New Zealand, Wellington, New Zealand.
Reddel HK; Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.
Ebmeier S; Medical Research Institute of New Zealand, Wellington, New Zealand.
Hancox RJ; Department of Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand; Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
Harrison T; Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Houghton C; Medical Research Institute of New Zealand, Wellington, New Zealand.
Oldfield K; Medical Research Institute of New Zealand, Wellington, New Zealand.
Papi A; Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy.
Williams M; Medical Research Institute of New Zealand, Wellington, New Zealand.
Weatherall M; University of Otago Wellington, Wellington, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand.
Pokaż więcej
Corporate Authors :
Novel START Study Team
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2020 Jul; Vol. 8 (7), pp. 671-680. Date of Electronic Publication: 2020 Mar 11.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Eosinophils*
Leukocyte Count*
Asthma/*drug therapy
Asthma/*metabolism
Bronchodilator Agents/*therapeutic use
Nitric Oxide/*metabolism
Adult ; Albuterol/therapeutic use ; Budesonide/therapeutic use ; Exhalation ; Female ; Formoterol Fumarate/therapeutic use ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Optimal Asthma Control: Time for a New Target.
Autorzy :
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Victoria University of Wellington, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.
Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand.
Kearns C; Medical Research Institute of New Zealand, Wellington, New Zealand.
Weatherall M; Capital & Coast District Health Board, Wellington, New Zealand.; University of Otago Wellington, Wellington, New Zealand; and.
Pavord ID; Oxford Respiratory National Institute for Health Research Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Pokaż więcej
Źródło :
American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2020 Jun 15; Vol. 201 (12), pp. 1480-1487.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Practice Guidelines as Topic*
Adrenal Cortex Hormones/*therapeutic use
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Anti-Asthmatic Agents/*therapeutic use
Asthma/*drug therapy
Administration, Inhalation ; Administration, Oral ; Asthma/physiopathology ; Humans ; Quality of Life ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Achieving the balance between evidence and simplicity.
Autorzy :
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand .; Capital and Coast District Health Board, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Kearns C; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Weatherall M; Capital and Coast District Health Board, Wellington, New Zealand.; University of Otago Wellington, Wellington, New Zealand.
Harrison T; Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Papi A; Respiratory Medicine Unit, Dept of Medical Sciences, Università di Ferrara, Ferrara, Italy.
Pavord ID; Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2020 Apr 30; Vol. 55 (4). Date of Electronic Publication: 2020 Apr 30 (Print Publication: 2020).
Typ publikacji :
Letter; Comment
MeSH Terms :
Algorithms*
Asthma*
Adult ; Formoterol Fumarate ; Humans
Opinia redakcyjna
Tytuł :
ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma.
Autorzy :
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand .; Capital and Coast District Health Board, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Kearns C; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Weatherall M; Capital and Coast District Health Board, Wellington, New Zealand.; University of Otago Wellington, Wellington, New Zealand.
Harrison TW; Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Papi A; Respiratory Medicine Unit, Dept of Medical Sciences, Università di Ferrara, Ferrara, Italy.
Pavord ID; Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2020 Jan 09; Vol. 55 (1). Date of Electronic Publication: 2020 Jan 09 (Print Publication: 2020).
Typ publikacji :
Editorial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Asthmatic Agents*/therapeutic use
Asthma*/drug therapy
Administration, Inhalation ; Adult ; Algorithms ; Bronchodilator Agents/therapeutic use ; Budesonide/therapeutic use ; Drug Combinations ; Ethanolamines ; Formoterol Fumarate/therapeutic use ; Humans ; Treatment Outcome
Raport
Tytuł :
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Autorzy :
Beasley R; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Holliday M; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Reddel HK; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Braithwaite I; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Ebmeier S; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Hancox RJ; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Harrison T; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Houghton C; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Oldfield K; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Papi A; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Pavord ID; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Williams M; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Weatherall M; From the Medical Research Institute of New Zealand (R.B., M.H., I.B., S.E., C.H., K.O., M. Williams), the Capital and Coast District Health Board (R.B.), and the University of Otago Wellington (M. Weatherall), Wellington, the Department of Respiratory Medicine, Waikato Hospital, Hamilton (R.J.H.), and the Department of Preventive and Social Medicine, University of Otago, Dunedin (R.J.H.) - all in New Zealand; Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); the Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham (T.H.), and the Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford (I.D.P.) - both in the United Kingdom; and the Respiratory Medicine Unit, Department of Medical Sciences, Università di Ferrara, Ferrara, Italy (A.P.).
Pokaż więcej
Corporate Authors :
Novel START Study Team
Źródło :
The New England journal of medicine [N Engl J Med] 2019 May 23; Vol. 380 (21), pp. 2020-2030. Date of Electronic Publication: 2019 May 19.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Albuterol/*administration & dosage
Asthma/*drug therapy
Bronchodilator Agents/*administration & dosage
Budesonide/*administration & dosage
Formoterol Fumarate/*administration & dosage
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adult ; Aged ; Albuterol/adverse effects ; Bronchodilator Agents/adverse effects ; Budesonide/adverse effects ; Drug Therapy, Combination ; Female ; Formoterol Fumarate/adverse effects ; Humans ; Male ; Metered Dose Inhalers ; Middle Aged
Czasopismo naukowe
Tytuł :
Change in biomarkers of type-2 inflammation following severe exacerbations of asthma.
Autorzy :
Semprini R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Victoria University Wellington, Wellington, New Zealand.
Shortt N; Medical Research Institute of New Zealand, Wellington, New Zealand.; Victoria University Wellington, Wellington, New Zealand.
Ebmeier S; Medical Research Institute of New Zealand, Wellington, New Zealand.
Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand.; Victoria University Wellington, Wellington, New Zealand.
Varughese R; Medical Research Institute of New Zealand, Wellington, New Zealand.
Holweg CTJ; Genentech Inc, South San Francisco, California, USA.
Matthews JG; Genentech Inc, South San Francisco, California, USA.
Fingleton J; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.
Weatherall M; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.; University of Otago, Wellington, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Victoria University Wellington, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.
Pokaż więcej
Źródło :
Thorax [Thorax] 2019 Jan; Vol. 74 (1), pp. 95-98. Date of Electronic Publication: 2018 Jul 18.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Eosinophils*
Symptom Flare Up*
Asthma/*blood
Cell Adhesion Molecules/*blood
Immunoglobulin E/*blood
Adolescent ; Adult ; Aged ; Biomarkers/blood ; Breath Tests ; Humans ; Leukocyte Count ; Middle Aged ; Nitric Oxide/analysis ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma.
Autorzy :
Semprini R; Medical Research Institute of New Zealand, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand.
Williams M; Medical Research Institute of New Zealand, Wellington, New Zealand.
Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand.
McDouall A; Medical Research Institute of New Zealand, Wellington, New Zealand; University of Otago, Wellington, New Zealand.
Fingleton J; Medical Research Institute of New Zealand, Wellington, New Zealand; Capital & Coast District Health Board, Wellington, New Zealand.
Holweg C; Genentech Inc, South San Francisco, Calif.
Weatherall M; University of Otago, Wellington, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand; Victoria University of Wellington, Wellington, New Zealand; Capital & Coast District Health Board, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand; Capital & Coast District Health Board, Wellington, New Zealand. Electronic address: Irene.braithwaite@mrinz.ac.nz.
Pokaż więcej
Źródło :
The journal of allergy and clinical immunology. In practice [J Allergy Clin Immunol Pract] 2018 Nov - Dec; Vol. 6 (6), pp. 1982-1988.e1. Date of Electronic Publication: 2018 Mar 30.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Asthma/*diagnosis
Biomarkers/*metabolism
Cell Adhesion Molecules/*blood
Eosinophils/*immunology
Immunoglobulin E/*blood
Lung/*physiology
Nitric Oxide/*metabolism
Adult ; Aged ; Asthma/epidemiology ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; New Zealand/epidemiology ; Respiratory Function Tests ; Risk
Czasopismo naukowe
Tytuł :
Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial.
Autorzy :
Bardsley G; Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington, 6242, New Zealand.
Daley-Yates P; Respiratory Clinical Development, GlaxoSmithKline Research and Development, Stockley Park, Uxbridge, UK.
Baines A; Medicines Development Centre, GlaxoSmithKline Research and Development, Stevenage, UK.
Kempsford R; Medicines Development Centre, GlaxoSmithKline Research and Development, Stevenage, UK.
Williams M; Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington, 6242, New Zealand.
Mallon T; Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington, 6242, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington, 6242, New Zealand.
Riddell K; GlaxoSmithKline Research and Development, 82 Hughes Ave, Ermington, NSW, 2115, Australia.
Joshi S; Quantitative sciences, GlaxoSmithKline, Bangalore, India.
Bareille P; Medicines Development Centre, GlaxoSmithKline Research and Development, Stevenage, UK.
Beasley R; Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington, 6242, New Zealand.
Fingleton J; Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington, 6242, New Zealand. .
Pokaż więcej
Corporate Authors :
study team
Źródło :
Respiratory research [Respir Res] 2018 Jul 13; Vol. 19 (1), pp. 133. Date of Electronic Publication: 2018 Jul 13.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Androstadienes/*administration & dosage
Anti-Inflammatory Agents/*administration & dosage
Asthma/*diagnosis
Asthma/*drug therapy
Benzyl Alcohols/*administration & dosage
Chlorobenzenes/*administration & dosage
Adolescent ; Adult ; Asthma/epidemiology ; Cross-Over Studies ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Male ; Prospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Association between Frequency of Consumption of Fruit, Vegetables, Nuts and Pulses and BMI: Analyses of the International Study of Asthma and Allergies in Childhood (ISAAC).
Autorzy :
Wall CR; Discipline of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, University of Auckland, Auckland 1010, New Zealand. .
Stewart AW; School of Population Health, University of Auckland, Auckland 1010, New Zealand. .
Hancox RJ; Department of Preventive & Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand. .
Murphy R; Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland 1010, New Zealand. .
Braithwaite I; Medical Research Institute of New Zealand, Wellington 6021, New Zealand. Irene.Braithwaite@mrinz.ac.nz.
Beasley R; Medical Research Institute of New Zealand, Wellington 6021, New Zealand. .
Mitchell EA; Department of Paediatrics: Child and Youth Health, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland 1010, New Zealand. .
Pokaż więcej
Corporate Authors :
ISAAC Phase Three Study Group
Źródło :
Nutrients [Nutrients] 2018 Mar 07; Vol. 10 (3). Date of Electronic Publication: 2018 Mar 07.
Typ publikacji :
Journal Article
MeSH Terms :
Body Mass Index*
Fabaceae*
Fruit*
Nuts*
Vegetables*
Asthma/*epidemiology
Hypersensitivity/*epidemiology
Adolescent ; Child ; Cross-Sectional Studies ; Diet ; Female ; Humans ; Male ; Pediatric Obesity/epidemiology ; Prevalence ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
The inhaled corticosteroid/long-acting β-agonist maintenance and reliever therapy regimen: where to from here?
Autorzy :
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand .
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.
Fingleton J; Medical Research Institute of New Zealand, Wellington, New Zealand.
Weatherall M; University of Otago, Wellington, New Zealand.
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2018 Jan 04; Vol. 51 (1). Date of Electronic Publication: 2018 Jan 04 (Print Publication: 2018).
Typ publikacji :
Editorial; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Asthma*
Formoterol Fumarate*
Administration, Inhalation ; Adolescent ; Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Bronchodilator Agents ; Budesonide ; Drug Therapy, Combination ; Ethanolamines ; Humans
Raport
Tytuł :
Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012).
Autorzy :
Ebmeier S; Medical Research Institute of New Zealand, Wellington, New Zealand.
Thayabaran D; Medical Research Institute of New Zealand, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.
Bénamara C; Medical Research Institute of New Zealand, Wellington, New Zealand.
Weatherall M; Department of Medicine, University of Otago Wellington, Wellington, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand. Electronic address: .
Pokaż więcej
Źródło :
Lancet (London, England) [Lancet] 2017 Sep 02; Vol. 390 (10098), pp. 935-945. Date of Electronic Publication: 2017 Aug 07.
Typ publikacji :
Journal Article
MeSH Terms :
Data Interpretation, Statistical*
Databases, Factual*
World Health Organization*
Asthma/*mortality
Mortality/*trends
Adolescent ; Adult ; Cause of Death ; Child ; Child, Preschool ; Female ; Global Health ; Humans ; Male ; Young Adult
Czasopismo naukowe
Tytuł :
Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial.
Autorzy :
Pilcher J; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.
Patel M; Medical Research Institute of New Zealand, Wellington, New Zealand.; Nottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.; Chest Clinic, Derriford Hospital, Plymouth, UK.
Pritchard A; Medical Research Institute of New Zealand, Wellington, New Zealand.
Thayabaran D; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.
Ebmeier S; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.
Shaw D; Nottingham Respiratory Research Unit, School of Medicine, University of Nottingham, Nottingham, UK.
Black P; University of Auckland, Auckland, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand. Irene.braithwaite@mrinz.ac.nz.
Weatherall M; Capital & Coast District Health Board, Wellington, New Zealand.; University of Otago, Wellington, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital & Coast District Health Board, Wellington, New Zealand.; University of Otago, Wellington, New Zealand.
Pokaż więcej
Źródło :
NPJ primary care respiratory medicine [NPJ Prim Care Respir Med] 2017 May 11; Vol. 27 (1), pp. 33. Date of Electronic Publication: 2017 May 11.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Prescription Drug Overuse*
Albuterol/*administration & dosage
Anti-Asthmatic Agents/*administration & dosage
Asthma/*drug therapy
Budesonide, Formoterol Fumarate Drug Combination/*administration & dosage
Administration, Inhalation ; Adult ; Asthma/diagnosis ; Drug Therapy, Combination ; Female ; Humans ; Male ; Nebulizers and Vaporizers ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Longitudinal variation of serum periostin levels in adults with stable asthma.
Autorzy :
Semprini R; Medical Research Institute of New Zealand, Wellington, New Zealand; Faculty of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand. Electronic address: .
Caswell-Smith R; Medical Research Institute of New Zealand, Wellington, New Zealand; Faculty of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
Fingleton J; Medical Research Institute of New Zealand, Wellington, New Zealand.
Holweg C; OMNI - Biomarker Development, Genentech, South San Francisco, Calif.
Matthews J; OMNI - Biomarker Development, Genentech, South San Francisco, Calif.
Weatherall M; Department of Medicine, University of Otago, Dunedin, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand; Faculty of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand; Faculty of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
Pokaż więcej
Corporate Authors :
Periostin Study Team
Źródło :
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2017 May; Vol. 139 (5), pp. 1687-1688.e9. Date of Electronic Publication: 2017 Jan 16.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Adrenal Cortex Hormones/*therapeutic use
Anti-Asthmatic Agents/*therapeutic use
Asthma/*diagnosis
Biomarkers/*blood
Cell Adhesion Molecules/*blood
Adolescent ; Adult ; Aged ; Asthma/drug therapy ; Cohort Studies ; Disease Progression ; Drug Resistance ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Young Adult
Raport
Tytuł :
RCT of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study.
Autorzy :
Power S; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Williams M; Medical Research Institute of New Zealand, Wellington, New Zealand.
Semprini A; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.; Victoria University of Wellington, Wellington, New Zealand.
Munro C; University of Otago, Wellington, New Zealand.
Caswell-Smith R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.; Victoria University of Wellington, Wellington, New Zealand.
Pilcher J; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.; Victoria University of Wellington, Wellington, New Zealand.
Holliday M; Medical Research Institute of New Zealand, Wellington, New Zealand.
Fingleton J; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.; Victoria University of Wellington, Wellington, New Zealand.
Harper J; Malaghan Institute of Medical Research, Wellington, New Zealand.
Hurst R; The New Zealand Institute for Plant & Food Research, Palmerston North, New Zealand.
Weatherall M; Capital and Coast District Health Board, Wellington, New Zealand.; University of Otago, Wellington, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand.; Capital and Coast District Health Board, Wellington, New Zealand.; Victoria University of Wellington, Wellington, New Zealand.
Pokaż więcej
Źródło :
BMJ open [BMJ Open] 2017 Mar 20; Vol. 7 (3), pp. e013850. Date of Electronic Publication: 2017 Mar 20.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Fruit*
Anti-Asthmatic Agents/*therapeutic use
Asthma/*drug therapy
Phytotherapy/*methods
Plant Extracts/*pharmacology
Adolescent ; Adult ; Aged ; Cross-Over Studies ; Double-Blind Method ; Female ; Forced Expiratory Volume ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Pilot study of feasibility of a randomised controlled trial of asthma risk with paracetamol versus ibuprofen use in infancy.
Autorzy :
Riley J; Research Nurse, Medical Research Institute of New Zealand, Wellington.
Hunt A; Research Nurse, Medical Research Institute of New Zealand, Wellington.
McDouall A; Summer Student, Medical Research Institute of New Zealand, Wellington.
Waqanivavalagi S; Summer Student, The University of Auckland, Auckland.
Braithwaite I; Research Fellow, Medical Research Institute of New Zealand, Wellington.
Weatherall M; Consultant Geriatrician, Capital and Coast District Health Board, Professor of Medicine, University of Otago, Wellington.
Stanley T; Consultant Paediatrician, Capital and Coast District Health Board, Senior Lecturer, University of Otago, Wellington.
Beasley R; Director, Medical Research Institute of New Zealand, Respiratory Physician, Capital and Coast District Health Board, Wellington.
Mitchell EA; Professor, Paediatrics (Child and Youth Health), School of Medicine, The University of Auckland, Auckland.
Dalziel SR; Specialist, Liggins Institute, The University of Auckland, Paediatric Emergency Medicine Specialist, Auckland District Health Board, Auckland.
Pokaż więcej
Źródło :
The New Zealand medical journal [N Z Med J] 2016 Oct 14; Vol. 129 (1443), pp. 30-42. Date of Electronic Publication: 2016 Oct 14.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Patient Selection*
Acetaminophen/*adverse effects
Analgesics, Non-Narcotic/*adverse effects
Asthma/*epidemiology
Ibuprofen/*adverse effects
Asthma/etiology ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; New Zealand ; Parents ; Pilot Projects ; Risk Factors ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
Autorzy :
Braithwaite I; Medical Research Institute of New Zealand, Wellington, New Zealand. Electronic address: Irene.Braithwaite@mrinz.ac.nz.
Williams M; Medical Research Institute of New Zealand, Wellington, New Zealand.
Power S; Medical Research Institute of New Zealand, Wellington, New Zealand.
Pilcher J; Medical Research Institute of New Zealand, Wellington, New Zealand.
Weatherall M; Rehabilitation Teaching and Research Unit, University of Otago Wellington, Wellington, New Zealand.
Baines A; Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, UK.
Moynihan J; Synergy Clinical, Langley, UK.
Kempsford R; Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, UK.
Beasley R; Medical Research Institute of New Zealand, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand.
Pokaż więcej
Corporate Authors :
FF/VI Study Team
Źródło :
Respiratory medicine [Respir Med] 2016 Oct; Vol. 119, pp. 115-121. Date of Electronic Publication: 2016 Sep 04.
Typ publikacji :
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Albuterol/*administration & dosage
Androstadienes/*administration & dosage
Asthma/*drug therapy
Benzyl Alcohols/*administration & dosage
Chlorobenzenes/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Adolescent ; Adrenal Cortex Hormones/therapeutic use ; Adrenergic beta-2 Receptor Agonists/therapeutic use ; Adult ; Aged ; Albuterol/pharmacology ; Androstadienes/pharmacology ; Asthma/physiopathology ; Benzyl Alcohols/pharmacology ; Bronchodilator Agents/therapeutic use ; Chlorobenzenes/pharmacology ; Cross-Over Studies ; Double-Blind Method ; Drug Combinations ; Female ; Forced Expiratory Volume/drug effects ; Humans ; Male ; Middle Aged ; New Zealand/epidemiology ; Placebos ; Pulmonary Disease, Chronic Obstructive/physiopathology ; Young Adult
Czasopismo naukowe
Tytuł :
Randomized controlled trial of asthma risk with paracetamol use in infancy--a feasibility study.
Autorzy :
Riley J; Medical Research Institute of New Zealand, Wellington, New Zealand.
Braithwaite I
Shirtcliffe P
Caswell-Smith R
Hunt A
Bowden V
Power S
Stanley T
Crane J
Ingham T
Weatherall M
Mitchell EA
Beasley R
Pokaż więcej
Źródło :
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2015 Feb; Vol. 45 (2), pp. 448-56.
Typ publikacji :
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Acetaminophen/*adverse effects
Asthma/*epidemiology
Asthma/*etiology
Acetaminophen/administration & dosage ; Adult ; Age Factors ; Feasibility Studies ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Patient Outcome Assessment ; Risk ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis.
Autorzy :
Patel M; 1] Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham, UK [2] Medical Research Institute of New Zealand, Wellington, New Zealand.
Pilcher J; 1] Medical Research Institute of New Zealand, Wellington, New Zealand [2] Capital & Coast District Health Board, Wellington, New Zealand.
Hancox RJ; 1] Respiratory Medicine, Waikato Hospital, Hamilton, New Zealand [2] Department of Preventive & Social Medicine, University of Otago, Dunedin, New Zealand.
Sheahan D; Papamoa Pines Medical Centre, Tauranga, New Zealand.
Pritchard A; Medical Research Institute of New Zealand, Wellington, New Zealand.
Braithwaite I; 1] Medical Research Institute of New Zealand, Wellington, New Zealand [2] Capital & Coast District Health Board, Wellington, New Zealand.
Shaw D; Division of Respiratory Medicine, School of Medicine, University of Nottingham, Nottingham, UK.
Black P; University of Auckland, Auckland, New Zealand.
Weatherall M; 1] Capital & Coast District Health Board, Wellington, New Zealand [2] University of Otago, Wellington, New Zealand.
Beasley R; 1] Medical Research Institute of New Zealand, Wellington, New Zealand [2] Capital & Coast District Health Board, Wellington, New Zealand [3] University of Otago, Wellington, New Zealand.
Pokaż więcej
Corporate Authors :
SMART Study Group
Źródło :
NPJ primary care respiratory medicine [NPJ Prim Care Respir Med] 2015 Jan 08; Vol. 25, pp. 14099. Date of Electronic Publication: 2015 Jan 08.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adrenergic beta-2 Receptor Agonists/*administration & dosage
Asthma/*drug therapy
Budesonide/*administration & dosage
Ethanolamines/*administration & dosage
Glucocorticoids/*administration & dosage
Adult ; Aged ; Disease Progression ; Female ; Formoterol Fumarate ; Hospitalization ; Humans ; Male ; Middle Aged
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies